Myeloma
The latest news, research, and perspectives in multiple myeloma. Multiple myeloma is characterized by the proliferation of malignant plasma cells that accumulate in the bone marrow and produce abnormal immunoglobulin. Read more about the pathophysiology, diagnosis, staging, and treatment of myeloma.
Advertisement
Novel therapies and “game-changing drugs” have made a major impact on the treatment of myeloma, Dr. Wong said.
Patients with clinical progression had a significantly shorter median OS from their first relapse.
Sandy Wong, MD, explains how clinicians and researchers can help educate others about myeloma.
Molly Stoddart, RN, BSN, is a clinical research nurse on the multiple myeloma team at the Winship Cancer Institute at Emory.
Around two-thirds of second primary malignancies were solid malignancies and 20% were myeloid malignancies.
Sandy Wong, MD, explains what Myeloma Awareness Month means to her as a clinician and a researcher.
Advertisement
The “greatest benefit" was observed in those who had t(4;14) or amp1q21.
Frailty measures have been "increasingly incorporated" in multiple myeloma trials in recent years.
Sagar Lonial, MD, FACP, Editor-in-Chief of Blood Cancers Today, discusses Multiple Myeloma Awareness Month.
Dr. Raje reflects on the mentors who shaped her career, the evolution of myeloma treatment, and more.
The four-year OS rate from the first randomization was 94% in patients without high-risk cytogenetic abnormalites.
The OPTIMUM/MUKnine clinical trial aimed to reduce the risk of relapse before and after AHSCT in ultrahigh-risk MM.
The new FDA decision follows its granting of Breakthrough Therapy Designation to elranatamab in November 2022.
Advocates hope it will bring much-needed changes to patient care for complex cancers—including hematologic malignancies.
The investigators plan to continue using the monitoring strategies and further study patient outcomes.
The research shows an emerging target for the development of novel CAR T-cell immunotherapies.
Idecabtagene vicleucel led to “deeper and more durable responses” than standard regimens in the KarMMa-3 trial.
Thomas G. Martin, MD, and Saad Z. Usmani, MD, MBA, FACP, debate CAR-T vs bispecific antibodies for R/R MM.
A triplet may improve PFS over lenalidomide alone in patients with multiple myeloma who underwent induction and AHSCT.
A new method to detect MRD in peripheral blood had an “unprecedented sensitivity” level in multiple myeloma.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
670 Madison Ave.
Manalapan, NJ 07726